May antidepressant drugs worsen the conditions they are supposed to treat? The clinical foundations of the oppositional model of tolerance
Open accessThe DOI matches its Crossref record; 83 of the 83 references it cites were found in a registry or an index; 45 of the 136 sources its claims cite were checked for support.
Abstract
In recent years there has been a considerable debate on antidepressant drugs. Continued drug treatment with antidepressant medications may stimulate processes that run counter to the initial acute effects of a drug. The oppositional model of tolerance may explain loss of treatment efficacy during maintenance treatment and the fact that some side effects tend to occur only after a certain time. These processes may also direct the illness into a treatment-unresponsive course, including manifestations of bipolar disorder or paradoxical reactions. When drug treatment ends, oppositional processes no longer encounter resistance, resulting in potential onset of new withdrawal symptoms, persistent post-withdrawal disorders, hypomania, and resistance to treatment if it is reinstituted. In all these cases, antidepressant medications may constitute a form of iatrogenic comorbidity, which increases chronicity and vulnerability to depressive episodes. Antidepressant medications are essential drugs for the treatment of major depressive episodes. They are less likely, however, to provide protection for relapse prevention. Current prescription practices need to be reformulated in light of consideration of vulnerabilities and adverse effects of treatment. The oppositional model of tolerance provides a conceptual framework for weighing all these elements in the individual case. The model does not appear to apply to all patients who undergo treatment with AD, but only to a part of them. Studying the variables that are associated with such occurrence in certain patients and not in others would be one of the most important tasks of current therapeutic research. Current diagnostic systems in psychiatry do not consider the iatrogenic components of psychopathology, and can be applied to only patients who are drug free. They are suited for a patient who no longer exists: most of the cases that are seen in psychiatric clinical practice receive psychotropic drugs and such treatment is likely to affect prognosis and treatment choices.
Overview
CoChat Summary
TL;DR
Fava reviews clinical evidence for the oppositional model of tolerance, arguing that antidepressant drugs can paradoxically worsen mood and anxiety disorders in some patients through loss of efficacy, resistance, paradoxical reactions, switching, withdrawal, and refractoriness. He concludes antidepressants remain essential for severe depression but that long-term and anxiety-disorder prescribing should be reconsidered; the model applies only to a fraction of patients and still awaits adequate testing.
Key findings
- The oppositional model posits three phases: early treatment (up to 6 weeks) with paradoxical reactions and hypomania/mania; long-term treatment with paradoxical reactions, hypomania/mania, loss of clinical effects, delayed side effects, and refractoriness; and post-treatment with new withdrawal symptoms, hypomania/mania, persistent post-withdrawal disorder, and resistance if the same treatment is reinstituted.
- Loss of antidepressant efficacy: in a meta-analysis of maintenance treatment studies, relapse risk increased from 23% within 1 year to 34% in 2 years and 45% in 3 years. In a fluoxetine maintenance study, about one-third relapsed within an average of 107 days; dose increase produced response in 57% of daily-dosage patients and 72% of weekly-dosage patients, and one in five initial dose responders relapsed again during the 25-week trial.
- Resistance/rechallenge: a systematic review found response failures ranging from 4.9% to 42.9%; a large observational study found failure to respond to the same medication in a quarter of cases; among 122 patients who initially responded to fluoxetine and were assigned to placebo, about half relapsed, and after fluoxetine re-initiation 38% did not respond at all or relapsed after an initial response.
- STAR*D: first open citalopram treatment yielded 37% remission and 15% who responded and stayed well for a year; cumulative remission after four sequential steps was 67%, but persistent recovery was 43%, with step one yielding only an additional 6% of sustained recovery; remission decreased after each step while relapse on medication and intolerance increased. A juvenile meta-analysis found excessive arousal-activation with antidepressants in anxiety (13.8%) and depression (9.8%) versus placebo (5.2% and 1.1%, respectively).
Methods
- Narrative/conceptual review by the originator of the oppositional model; the paper states it does not aim to be exhaustive and cites only illustrative investigations to outline clinical insights.
- Synthesizes clinical phenomena reported during or after antidepressant treatment: loss of antidepressant efficacy, resistance, paradoxical effects, switching to bipolar course, withdrawal reactions, and refractoriness.
- Draws on selected trials and meta-analyses (e.g., maintenance relapse meta-analysis, fluoxetine/duloxetine relapse studies, STAR*D, juvenile activation meta-analysis) to support the model; no new primary data are presented.
Limitations
- The paper states the model was “largely speculative” at its formulation and still awaits adequate preclinical and clinical research testing; it does not appear to apply to all patients treated with antidepressants, but only to a fraction, and the variables associated with occurrence in some patients remain to be studied.
- The paper states the review is not exhaustive and only illustrative investigations are cited.
- Evident from the text: this is a narrative review with selective citation by a proponent/originator of the model, without a systematic search or formal risk-of-bias assessment; many cited findings are from other studies and are not re-analyzed here.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
13 Valid · 2 Not valid · 67 Not checked · 34 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In a recent systematic review on lack of response to re-challenge,22 the range of response failures was broad (between 4.9% and 42.9% across studies).”
§ May antidepressant drugs worsen the conditions they are supposed to treat? The clinical foundations of the oppositional model of tolerance > The clinical foundations of the model of oppositional tolerance with antidepressant treatment > Resistance to antidepressant drugs
What the sources say
- Partly supportedcites [22] Bosman RC Waumans RC Jacobs GE, et al Failure to respond after reinstatement of antidepressant medication: a systematic review. Psychother Psychosom 2018; 87: 268– 275. 30041180 PMC6191880 sourceExperimental — accuracy not yet measured
The Results (p. 3) confirm that this systematic review found a broad range of response failures across studies, but report 3.8%–42.9%, not 4.9%–42.9%. The lower bound in the citing sentence is therefore unsupported. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The withdrawal syndrome encompasses a broad range of somatic symptoms (e.g. headache, dizziness, flu-like symptoms, nausea).”
§ May antidepressant drugs worsen the conditions they are supposed to treat? The clinical foundations of the oppositional model of tolerance > The clinical foundations of the model of oppositional tolerance with antidepressant treatment > Withdrawal syndromes
What the sources say
- Supportedcites [40] Fava GA Gatti A Belaise C, et al Withdrawal symptoms after selective serotonin reuptake inhibitor discontinuation: a systematic review. Psychother Psychosom 2015; 84: 72– 81. 25721705 source
The Discussion’s Table 1 lists a broad range of SSRI withdrawal symptoms, including all four examples: headache, dizziness, flu-like symptoms, and nausea. The Introduction also identifies dizziness, headache, and nausea as somatic symptoms. (LLM, conf=0.94)
- Supportedcites [41] Chouinard G Chouinard VA New classification of selective serotonin reuptake inhibitor withdrawal. Psychother Psychosom 2015; 84: 63– 71. 25721565 source
The “New Withdrawal Symptoms” section says SSRI withdrawal includes a wide range of physical symptoms and explicitly lists flu-like symptoms, headaches, nausea, and dizziness. Table 2 also lists these symptoms across multiple bodily systems. (LLM, conf=0.94)
- Supportedcites [42] Fava GA Benasi G Lucente M, et al Withdrawal symptoms after serotonin-noradrenaline reuptake inhibitors discontinuation: systematic review. Psychother Psychosom 2018; 87: 195– 203. 30016772 source
The Discussion (p. 5) describes a wide range of SNRI withdrawal manifestations. Its symptom table (p. 6) lists headache, dizziness, nausea, and symptoms consistent with a flu-like presentation, including fatigue, malaise, aches, and chills. (LLM, conf=0.91)
- Supportedcites [43] Davies J Read J A systematic review into the incidence, severity and duration of antidepressant withdrawal effects: are guideline evidence-based? Addict Behav 2019; 97: 111– 121. 30292574 source
The Introduction explicitly lists flu-like symptoms, nausea, dizziness, and headaches among antidepressant withdrawal reactions. It also describes these as common physical symptoms, supporting the claim that the syndrome includes a broad range of somatic symptoms. (LLM, conf=0.95)
- Partly supportedcites [44] Horowitz MA Taylor D Tapering of SSRI treatment to mitigate withdrawal symptoms. Lancet Psychiatry 2019; 6: 538– 546. 30850328 sourceExperimental — accuracy not yet measured
The section headed “SSRI withdrawal (‘discontinuation’) syndrome” (page unavailable) describes a wide variety of somatic symptoms and explicitly names dizziness and nausea. Our copy does not identify headache or flu-like symptoms as examples; searches for those terms found no matching passage. (LLM, conf=0.84)
- Supportedcites [45] Cosci F Chouinard G Acute and persistent withdrawal syndromes following discontinuation of psychotropic medications. Psychother Psychosom 2020; 89: 283– 306. 32259826 source
The Diagnostic criteria section (p. 2) identifies nausea, headaches, and flu-like symptoms as withdrawal symptoms. The symptom table (p. 5) and Antipsychotics section (p. 13) also list dizziness, supporting the claimed broad range of somatic symptoms. (LLM, conf=0.93)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“They have been described with any type of AD, but particularly with SSRI, venlafaxine, and duloxetine.”
§ May antidepressant drugs worsen the conditions they are supposed to treat? The clinical foundations of the oppositional model of tolerance > The clinical foundations of the model of oppositional tolerance with antidepressant treatment > Withdrawal syndromes
What the sources say
- Partly supportedcites [40] Fava GA Gatti A Belaise C, et al Withdrawal symptoms after selective serotonin reuptake inhibitor discontinuation: a systematic review. Psychother Psychosom 2015; 84: 72– 81. 25721705 sourceExperimental — accuracy not yet measured
Our copy supports the SSRI and venlafaxine parts: the whole systematic review documents withdrawal symptoms after SSRI discontinuation (Introduction; Table 1, Discussion), and the Multiple Drug Comparisons section reports venlafaxine XR discontinuation reactions (significantly more venlafaxine- than escitalopram-treated patients with DESS score >4 in a 1-week runout; Sir et al.'s sertraline vs. venlafaxine XR ADDS data). The 'any type of AD' generalisation is not made by this source, which states in Study Selection that 'we restricted our search to SSRI drugs'; other classes appear only in passing in the Discussion (benzofiazepines, antipsychotic drugs, tricyclic antidepressants). Duloxetine is not addressed at all in the body text — it occurs solely in the reference list (ref. 80, Bitter et al., 'Adverse reactions to duloxetine in depression'), so attributing duloxetine withdrawal to this review is unsupported. (LLM, conf=0.80)
- Partly supportedcites [41] Chouinard G Chouinard VA New classification of selective serotonin reuptake inhibitor withdrawal. Psychother Psychosom 2015; 84: 63– 71. 25721565 sourceExperimental — accuracy not yet measured
Our copy supports the general part: the Introduction states 'Withdrawal symptoms may occur with all SSRIs and serotonin-noradrenaline reuptake inhibitors (SNRIs) [1], similarly to other CNS drugs', and the New Withdrawal Symptoms section lists antidepressants among the CNS drug classes to which withdrawal symptoms are common, with SSRIs singled out throughout (paroxetine most, fluoxetine least). However, the specific attribution to venlafaxine and duloxetine is not supported: searches for 'venlafaxine' and 'duloxetine' returned no exact-phrase passage anywhere in our copy, and the paper's tables and diagnostic criteria address SSRI/SNRI withdrawal generically. The claim's 'particularly with ... venlafaxine and duloxetine' therefore goes beyond what this source states. (LLM, conf=0.78)
- Partly supportedcites [42] Fava GA Benasi G Lucente M, et al Withdrawal symptoms after serotonin-noradrenaline reuptake inhibitors discontinuation: systematic review. Psychother Psychosom 2018; 87: 195– 203. 30016772 sourceExperimental — accuracy not yet measured
Our copy supports the general framing and the venlafaxine part: the Introduction (p. 1) states withdrawal symptoms have been reported after reduction/discontinuation of antidepressant drugs including SSRI and SNRI, and the Discussion (p. 5) says prevalence 'appeared to be higher after discontinuation of venlafaxine' (23–78%, significantly above placebo in RCTs). It does not support singling out duloxetine as a particularly implicated drug: the same Discussion (p. 5) reports that withdrawal symptoms 'did not differ from placebo in most of the trials on duloxetine' (rates 6–55%; Results p. 4 gives 9.1–16.2% DEAE), and Results p. 3 shows duloxetine not differing from placebo in several comparisons. The claim's 'any type of AD' is also broader than this review's scope, which covers only the five SNRI and refers to SSRI as background (Abstract, p. 1 asks clinicians to add SNRI 'to the list of drugs potentially inducing withdrawal symptoms, together with other types of psychotropic drugs'). (LLM, conf=0.75)
- Partly supportedcites [43] Davies J Read J A systematic review into the incidence, severity and duration of antidepressant withdrawal effects: are guideline evidence-based? Addict Behav 2019; 97: 111– 121. 30292574 sourceExperimental — accuracy not yet measured
Our copy supports withdrawal across antidepressant types generally: the Introduction (Section 1) states antidepressants 'have been long known to induce withdrawal reactions in a large proportion of users (Haddad, 1997)' and quotes Fava et al. (2018, p. 195) that 'Withdrawal symptoms occurred after discontinuation of any type of SNRI' — note that the 'any type' wording in this paper is scoped to SNRIs, not to all antidepressants. Section 3.2 and Table 1 report incidence for SSRIs (e.g. paroxetine 76% and 100%, sertraline 60%), venlafaxine (70%, 60%, 82%) and duloxetine (69% in R.C.P., 2012), so the three named agents are covered. But the paper nowhere singles them out as the drugs with which withdrawal occurs 'particularly'; indeed in Read & Williams, 2018 (Table 1) duloxetine had the lowest reported rate (31%, 5/16), below paroxetine, tricyclics, fluoxetine, venlafaxine, escitalopram, citalopram and sertraline, and fluoxetine is consistently among the lowest (9–44%). The comparative emphasis attributed to this source is therefore not supported. (LLM, conf=0.75)
- Partly supportedcites [44] Horowitz MA Taylor D Tapering of SSRI treatment to mitigate withdrawal symptoms. Lancet Psychiatry 2019; 6: 538– 546. 30850328 sourceExperimental — accuracy not yet measured
Our copy fully supports the first half of the claim: the Abstract (section 'SSRI withdrawal (discontinuation) syndrome') states that 'All major classes of antidepressants - MAOIs, TCAs, SSRIs, and SNRIs - are associated with withdrawal symptoms', echoed in the Abstract summary ('All antidepressant classes are associated with a withdrawal syndrome'). The emphasis on SSRIs is consistent with the paper's focus, and it does note that short half-life agents (paroxetine) produce more frequent, quicker-onset and more severe withdrawal (Pharmacological characteristics of SSRI withdrawal). However, the paper nowhere singles out venlafaxine and duloxetine as drugs particularly associated with withdrawal symptoms — those two agents appear only in the titles of cited references (refs 39 Benazzi 'Venlafaxine Withdrawal Symptoms'; 56 Perahia 'Symptoms following abrupt discontinuation of duloxetine'), not in the body text, so that specific part of the claim is not attributable to this source. (LLM, conf=0.75)
- Supportedcites [45] Cosci F Chouinard G Acute and persistent withdrawal syndromes following discontinuation of psychotropic medications. Psychother Psychosom 2020; 89: 283– 306. 32259826 source
Our copy reviews withdrawal phenomena across every antidepressant class (TCAs, MAOIs, trazodone, mirtazapine/mianserin, bupropion, agomelatine — Antidepressants, p. 9) and states new withdrawal symptoms 'may occur with any type of SSRI' (p. 10), so the 'any type of AD' part is supported. The emphasis on SSRIs and venlafaxine is explicit: SSRI withdrawal is 'widely documented' (p. 10) and, among SNRIs, prevalence 'was highest after the discontinuation of venlafaxine (23 to 78%)' with duloxetine named among the SNRIs producing new withdrawal symptoms (p. 10) and as the subject of a long-term duloxetine withdrawal/persistent post-withdrawal report (p. 11). The only nuance is that the source singles out paroxetine rather than duloxetine as the most severe SSRI, but it does describe withdrawal for all three agents the claim lists. (LLM, conf=0.82)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“This time can be shortened to 3 months before tapering if the sequential combination of pharmacotherapy and psychotherapy is employed.63”
§ May antidepressant drugs worsen the conditions they are supposed to treat? The clinical foundations of the oppositional model of tolerance > The oppositional model as a conceptual clinical framework > Long-term treatment for relapse prevention
What the sources say
- Partly supportedcites [63] Guidi J Tomba E Fava GA The sequential integration of pharmacotherapy and psychotherapy in the treatment of major depressive disorder: a meta-analysis of the sequential model and a critical review of the literature. Am J Psychiatry 2016; 173: 128– 137. 26481173 sourceExperimental — accuracy not yet measured
Our copy supports only the qualitative frame: the Sequential Treatment discussion (Discussion of included studies) states that 'the number needed to treat showed a greater advantage of the sequential option with drug tapering and discontinuation in preventing relapse or recurrence compared with continuation of antidepressants' and that 'discontinuation of antidepressant drugs is feasible when psychotherapy is provided,' and the subgroup analysis (Sequential Use of Psychotherapy After Discontinuation of Antidepressant Medication) reports a pooled risk ratio of 0.674 (NNT=5) for that subgroup. However, no passage states that the time needed for satisfactory remission can be shortened, let alone to 3 months before tapering; searches for duration before tapering, '3 months', and time to remission returned nothing on that point. On the contrary, the Limitations section notes that 'the duration of treatments ... varied across the included studies,' that 'meta-regression analyses did not show significant effects on relapse/recurrence rates,' and that 'No controlled studies ... have directly compared the use of psychotherapy during antidepressant continuation with tapering and discontinuation,' so the specific 3-month reduction attributed to this source is not supported. (LLM, conf=0.65)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“However, in due course after their introduction, more pronounced problems occurred with most of the newer antidepressants.40–46”
§ May antidepressant drugs worsen the conditions they are supposed to treat? The clinical foundations of the oppositional model of tolerance > The oppositional model as a conceptual clinical framework > Antidepressant drugs in anxiety disorders
What the sources say
- Partly supportedcites [40] Fava GA Gatti A Belaise C, et al Withdrawal symptoms after selective serotonin reuptake inhibitor discontinuation: a systematic review. Psychother Psychosom 2015; 84: 72– 81. 25721705 sourceExperimental — accuracy not yet measured
The Introduction (page not provided) describes withdrawal reactions documented after SSRIs were introduced. But the Multiple Drug Comparisons and Withdrawal Symptoms in Retrospective Studies sections report substantial differences among antidepressants; they do not establish that problems were more pronounced with most newer antidepressants than with older ones. (LLM, conf=0.84)
- Partly supportedcites [41] Chouinard G Chouinard VA New classification of selective serotonin reuptake inhibitor withdrawal. Psychother Psychosom 2015; 84: 63– 71. 25721565 sourceExperimental — accuracy not yet measured
The introduction and New Withdrawal Symptoms section report withdrawal problems with SSRIs and SNRIs, including symptoms that vary in severity by drug. The paper does not establish that problems became more pronounced after these antidepressants were introduced, or that this occurred with most newer antidepressants. Page numbers were not available in our copy. (LLM, conf=0.82)
- Partly supportedcites [42] Fava GA Benasi G Lucente M, et al Withdrawal symptoms after serotonin-noradrenaline reuptake inhibitors discontinuation: systematic review. Psychother Psychosom 2018; 87: 195– 203. 30016772 sourceExperimental — accuracy not yet measured
The Results (p. 4) report substantial withdrawal symptoms after discontinuation of some SNRIs, particularly venlafaxine and desvenlafaxine. The paper does not establish that problems became more pronounced after the introduction of newer antidepressants or that this occurred with most of them. (LLM, conf=0.82)
- Partly supportedcites [43] Davies J Read J A systematic review into the incidence, severity and duration of antidepressant withdrawal effects: are guideline evidence-based? Addict Behav 2019; 97: 111– 121. 30292574 sourceExperimental — accuracy not yet measured
The Introduction (page unavailable) reports that antidepressant withdrawal can be severe and long-lasting, including with SNRIs. The paper does not establish that problems became more pronounced after newer antidepressants were introduced, or that this occurred with most of them. (LLM, conf=0.82)
- Partly supportedcites [44] Horowitz MA Taylor D Tapering of SSRI treatment to mitigate withdrawal symptoms. Lancet Psychiatry 2019; 6: 538– 546. 30850328 sourceExperimental — accuracy not yet measured
The paper’s ‘SSRI withdrawal’ section reports withdrawal symptoms across antidepressant classes, and its discussion of SSRI withdrawal describes symptoms that can be severe. It does not establish that problems became more pronounced after newer antidepressants were introduced, or that this occurred with most of them. (LLM, conf=0.78)
- Partly supportedcites [45] Cosci F Chouinard G Acute and persistent withdrawal syndromes following discontinuation of psychotropic medications. Psychother Psychosom 2020; 89: 283– 306. 32259826 sourceExperimental — accuracy not yet measured
The Antidepressants section (p. 10) says SSRIs are the leading cause of withdrawal, followed by SNRIs, supporting problems with these newer classes. But it does not establish that problems were more pronounced with most newer antidepressants: it says evidence for other recently introduced antidepressants is limited (pp. 9–10), and that withdrawal severity varies by drug (p. 10). (LLM, conf=0.82)
- Partly supportedcites [46] Hengartner MP Davies J Read J Antidepressant withdrawal – the tide is finally turning. Epidemiol Psych Sci 2019; 29: e52. PMC8061160 31434594 sourceExperimental — accuracy not yet measured
The paper’s Abstract says SSRI and SNRI withdrawal reactions are common and that severe withdrawal has been underestimated. It does not establish that problems were more pronounced with most newer antidepressants than with earlier drugs. (LLM, conf=0.82)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
73 more claims · 3 with their cited sources checked
Create a free account to see all 116 claims and to verify the 91 references still open.
- It may state two separate claims as one. 29
- Probably not a substantial claim. 9
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“These processes may also steer the mental disorder into a development of treatment-unresponsiveness, which may also include expressions of bipolar disorder or paradoxical reactions.”
From Successful use of tapering strips for hyperbolic reduction of antidepressant dose: a cohort study (2021) · cites this paper as [7]
The cited source says what the claim attributes to it.
In the citing paper
“When drug treatment ends, oppositional processes are no longer kept in check by resistance, resulting in a range of possible outcomes including new withdrawal symptoms, possible persistent post-withdrawal disorders (the existence of which has not been established firmly, more research being required), hypomania and resistance to treatment if it is reinitiated.7”
From Successful use of tapering strips for hyperbolic reduction of antidepressant dose: a cohort study (2021) · cites this paper as [7]
In the citing paper
“The ‘oppositional model of tolerance’ has been invoked to explain loss of treatment efficacy during maintenance treatment and the fact that some side effects tend to occur only after a certain time.”
From Successful use of tapering strips for hyperbolic reduction of antidepressant dose: a cohort study (2021) · cites this paper as [7]
In the citing paper
“It has been pointed out that continued drug treatment with antidepressant medications may stimulate processes that represent a reversal of the initial acute withdrawal effects of a drug.7”
From Successful use of tapering strips for hyperbolic reduction of antidepressant dose: a cohort study (2021) · cites this paper as [7]
Citations
Cites
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Selective publication of antidepressant trials and its influence on apparent efficacy
Turner, E. H., Matthews, A. M., Linardatos, E., Tell, R. A., & Rosenthal, R. (2008) · New England Journal of Medicine · doi:10.1056/nejmsa065779 · Cited by 2,435
Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review
Geddes, J. R., Carney, S. M., Davies, C., Furukawa, T. A., Kupfer, D. J., Frank, E., & Goodwin, G. M. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12599-8 · Cited by 945
Fava, M., Rush, A. J., Alpert, J. E., Balasubramani, G. K., Wisniewski, S. R., Carmin, C. N., Biggs, M. M., Zisook, S., Leuchter, A., Howland, R., et al. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.06111868 · Cited by 927
Keller, M. B. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820100053010 · Cited by 864
X-ray structures and mechanism of the human serotonin transporter
Coleman, J. A., Green, E. M., & Gouaux, E. (2016) · Nature · doi:10.1038/nature17629 · Cited by 668
Carvalho, A. F., Sharma, M. S., Brunoni, A. R., Vieta, E., & Fava, G. A. (2016) · Psychotherapy and Psychosomatics · doi:10.1159/000447034 · Cited by 650
Self-citationFava, G. A., Gatti, A., Belaise, C., Guidi, J., & Offidani, E. (2015) · Psychotherapy and Psychosomatics · doi:10.1159/000370338 · Cited by 436
Self-citationCourse of the Manic-Depressive Cycle and Changes Caused by Treatments
Kukopulos, A., Reginaldi, D., Laddomada, P., Floris, G., Serra, G., & Tondo, L. (2008) · Pharmacopsychiatry · doi:10.1055/s-2007-1019628 · Cited by 436
Davies, J., & Read, J. (2019) · Addictive Behaviors · doi:10.1016/j.addbeh.2018.08.027 · Cited by 387
Research works printed but not linked: 1
- Goodwin FK The biology of recurrence: new directions for the pharmacological bridge. J Clin Psychiatry 1989; 50(Suppl. 40–44): discussion 45– 47. 2689436
Cited by
The serotonin theory of depression: a systematic umbrella review of the evidence
Moncrieff, J., Cooper, R. E., Stockmann, T., Amendola, S., Hengartner, M. P., & Horowitz, M. A. (2023) · Molecular Psychiatry · doi:10.1038/s41380-022-01661-0 · Cited by 960
Major Depression and Its Recurrences: Life Course Matters
Monroe, S. M., & Harkness, K. L. (2022) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-072220-021440 · Cited by 608
A cultural-ecosocial systems view for psychiatry
Gómez-Carrillo, A., & Kirmayer, L. J. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1031390 · Cited by 101
Framer, A. (2021) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125321991274 · Cited by 73
Gastaldon, C., Schoretsanitis, G., Arzenton, E., Raschi, E., Papola, D., Ostuzzi, G., Moretti, U., Seifritz, E., Kane, J. M., Trifirò, G., et al. (2022) · Drug Safety · doi:10.1007/s40264-022-01246-4 · Cited by 64
Metadata
- Authors
- Fava, G. A.
- Affiliations
- Erie County Medical Center (US)
- Corresponding author
- Fava, Giovanni A.
- ORCID
- Fava, Giovanni A.
- Venue
- Therapeutic Advances in Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2020-01
- Volume
- 10
- Pages
- 2045125320970325-2045125320970325
- ISSN
- 2045-1253 (ISSN-L)
- 2045-1261
- PMC
- PMC7649913
- OpenAlex
- W3097539185
- Semantic Scholar
- fa5f0fc2a75d0bea748eb4950b4b15a20bba82fd
- Cited by
- 84
- References
- 83
- Citations by year
- 2026: 9 · 2025: 18 · 2024: 18 · 2023: 15 · 2022: 12 · 2021: 10
- FWCI
- 1.21
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Therapeutic Advances in Psychopharmacology (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Keywords
- antidepressants, antidepressant side effects, paradoxical reaction, bipolar disorder, treatment-resistant depression, antidepressant withdrawal symptoms, hypomania, relapse prevention, major depressive episode, chronicity of depression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: May antidepressant drugs worsen the conditions they are supposed to treat? The clinical foundations of the oppositional model of tolerance. https://app.cochat.ai/papers/10.1177/2045125320970325
- The paper
- Fava, G. A. (2020). May antidepressant drugs worsen the conditions they are supposed to treat? The clinical foundations of the oppositional model of tolerance. Therapeutic Advances in Psychopharmacology. https://doi.org/10.1177/2045125320970325
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.